Clinical Trials Logo

Clinical Trial Summary

There is a lot of evidence to show that the yeast beta-glucan has immunomodulatory, anti-inflammatory, anti-infective effects.However,few work was done on the relationship between yeast bata-glucan and the immune function of diabetic patients. This is a randomized double-blind trial, aiming to study the effect of yeast beta-glucan on immune system of prediabetic patients. Firstly, the investigators will go into the efficacy of yeast beta-glucan on improving the clinical symptoms of prediabetics. Secondly, the investigators will study the mechanism of yeast beta-glucan on enhancing the immune function and improving the inflammatory response.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT03495362
Study type Interventional
Source Huazhong University of Science and Technology
Contact Liegang Liu, MD, PhD
Phone +86-27-83650522
Email liegangliu@gmail.com
Status Recruiting
Phase N/A
Start date March 13, 2018
Completion date March 2019

See also
  Status Clinical Trial Phase
Completed NCT01944904 - Investigation of the Ability of a Supplement to Increase Good Bacteria in the Human Intestine and Blood Sugar Levels N/A
Terminated NCT04286529 - Effect of 1,25-dihydroxyvitamin D3, Treatment on Insulin Secretion and Muscle Strength in Pre-diabetic Persons Phase 1
Completed NCT02756117 - The Effect of Acute Lysine Administration on α-aminoadipic Acid Phase 1
Completed NCT02482922 - Feasibility of an Interval Exercise and Nutrition Intervention to Reduce Cardiovascular Disease Risk Factors N/A
Completed NCT01579292 - A Mobile Based Diabetes Prevention Program N/A
Completed NCT03708419 - Personalized Glucose Optimization Through Nutritional Intervention N/A
Completed NCT02124590 - The Effect of Oral Carnitine Supplementation on MRS-derived Mitochondrial Function N/A
Completed NCT01411540 - Effects of a Wholegrain Diet on Body Composition and Energy Balance N/A
Suspended NCT03508739 - Glucagon-like Peptide-1 Metabolism and Acute Neprilysin Inhibition Phase 3
Completed NCT01980017 - Evaluation of the Ottawa Model for Smoking Cessation in Diabetes Education Programs N/A